MRC1 and renal pelvis/ureter urothelial carcinoma: Furthermore, recent data suggest that tumors with MMR deficiency are more responsive to immune checkpoint blockade than MMR-proficient tumors.28 It is possible that patients with LS-UTUC may derive greater benefit from anti–PD-1 therapy, suggesting an immediate clinical implication for screening and potential personalization of therapy in these patients.